DC-15442 / DeepCure - LARVOL DELTA

DeepCure Announces DC-15442 as Development Candidate, an Oral STAT6 Inhibitor with 100% in vivo inhibition of pSTAT6 and comparable efficacy to dupilumab across disease models (PRNewswire) - "In preclinical evaluations, DC-15442 achieved nearly 100% inhibition of pSTAT6 in the acute ovalbumin (OVA) allergy models, which outperforms IL-4Ra antibodies and other STAT6 inhibitors. In direct comparisons using the MC903 atopic dermatitis model, DC-15442 matched dupilumab's effectiveness, significantly reducing serum IgE levels to those seen in healthy controls. Additionally, DC-15442 has a dramatic effect on lung function in asthma models, restoring lung function to almost the same levels as healthy controls, with an effect superior to a leading JAK inhibitor (upadacitinib) and dexamethasone."

Preclinical • Allergy • Asthma • Atopic Dermatitis